What's new in antibiotics?

Dermatologic Clinics

Volumn 23, Issue 2, 2005, Pages 301-312

  Padmanabhan, Ravindran A ^a   LaRosa, Steven P ^a,b   Tomecki, Kenneth J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ASTEMIZOLE; AZTREONAM; CLARITHROMYCIN; CYCLOSPORIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DEXTROMETHORPHAN; DICLOXACILLIN; GATIFLOXACIN; LINEZOLID; MIDAZOLAM; MOXIFLOXACIN; NIFEDIPINE; ORITAVANCIN; OXACILLIN; PETHIDINE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TERFENADINE; TOBRAMYCIN; TRAMADOL; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VANCOMYCIN; VENLAFAXINE;

ABDOMINAL PAIN; AGITATION; ANEMIA; APLASTIC ANEMIA; ARTHRALGIA; ARTHRITIS; BACTEREMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; COLITIS; CONFUSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPERPYREXIA; HYPOGLYCEMIA; INSOMNIA; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; MEDICAL DOCUMENTATION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NERVE FIBER DEGENERATION; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PHLEBITIS; PHOTOTOXICITY; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TENDINITIS; THROMBOCYTOPENIA; TORSADE DES POINTES; TREATMENT WITHDRAWAL; TREMOR; VERTIGO; VOMITING;

EID: 17044379826     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2005.01.003     Document Type: Review

References (67)

1. E. Schweiger, and M.J. Weinberg Novel antibacterial agents for skin and skin structure infections J Am Acad Dermatol 50 3 2004 331 340
2. F.P. Tally, and M.F. DeBruin Development of daptomycin for Gram-positive infections J Antimicrob Chemother 46 2000 523 526
3. F.P. Tally, M. Zeckel, and M.M. Wasilewski Daptomycin: a novel agent for Gram-positive infections Expert Opin Investig Drugs 8 1999 1223 1238
4. P. Canepari, M. Boaretti, and M. del Mar Lleó Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY 146032) Antimicrob Agents Chemother 34 1990 1220 1226
5. M. Boaretti, P. Canepari, and M.M. Lleó The activity of daptomycin on Enterococcus faecium protoplasts: indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis J Antimicrob Chemother 31 1993 227 235
6. W.E. Alborn, N.E. Allen, and D.A. Preston Daptomycin disrupts membrane potential in growing Staphylococcus aureus Antimicrob Agents Chemother 35 1991 2282 2287
7. L.J. Wale, A.P. Shelton, and D. Greenwood Scanning electronmicroscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin J Med Microbiol 30 1 1989 45 49
8. US Food and Drug Administration Drug approvals list [cited 29 October 2003] Available at: http://www.fda.gov/cder/foi/label/2003/21572_cubicin_lbl.pdf 2003 Accessed April 10, 2004
9. L.P. Kotra Daptomycin Curr Opin Investig Drugs 2 2000 185 205
10. C.F. Carpenter, and H.F. Chambers Daptomycin for gram-positive infections Clin Infect Dis 38 2004 994 1000
11. J. Leggett, K. Totsuka, and S. Ebert Pharmacodynamic and pharmacokinetic parameters (PKPs) affecting activity of LY146032 against Staphylococcus aureus [abstract 154] Program and Abstracts of the Twenty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy 1987 American Society for Microbiology Washington, DC 123
12. N. Safdar, D.R. Andes, and W.A. Craig In vivo pharmacodynamic activity of daptomycin (DAP) against multiple bacterial pathogens [abstract 1769] Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy 1999 American Society of Microbiology Washington, DC 42
13. A. Louie, P. Kaw, and W. Liu The pharmacodynamics of daptomycin as determined for Staphylococcus aureus in a mouse thigh infection model [abstract 1770] Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy 1999 American Society for Microbiology Washington, DC 42
14. B.L. Lee, M. Sachdeva, and H.F. Chambers Effect of protein binding of daptomycin on MIC and antibacterial activity Antimicrob Agents Chemother 35 1991 2505 2508
15. F.B. Oleson, C.L. Berman, and J.B. Kirkpatrick Once-daily dosing decreases toxicity of daptomycin Toxicol Sci 48 Suppl 1 1999 S322
16. S.J. Brickner Oxazolidinone antibacterial agents Curr Pharm Des 2 1996 175 194
17. R.C. Moellering Jr A novel antimicrobial agent joins the battle against resistant bacteria [editorial] Ann Intern Med 130 1999 155 157
18. C. Ford, J. Hamel, and D. Stapert Oxazolidinones: a new class of antimicrobials Infect Med 16 1999 435 445
19. J.S. Daly, G.M. Eliopoulos, and S. Willey Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound Antimicrob Agents Chemother 32 1988 1341 1346
20. A.H. Lin, R.W. Murray, and T.J. Vidmar The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicoland lincomycin Antimicrob Agents Chemother 41 1997 2127 2131
21. S.M. Swaney, H. Aoki, and M.C. Ganoza The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria Antimicrob Agents Chemother 42 1998 3251 3255
22. D.I. Diekema, and R.N. Jones Oxazolidinones: a review Drugs 59 2000 7 16
23. G.E. Zurenko, B.H. Yagi, and R.D. Schaadt In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents Antimicrob Agents Chemother 40 1996 839 845
24. R.J. Wallace Jr, B.A. Brown-Elliott, and S.C. Ward Activities of linezolid against rapidly growing mycobacteria Antimicrob Agents Chemother 45 2001 764 767
25. J. Peters, K.L. Kondo, and R.K. Lee In-vitro activity of oxazolidinones against Mycobacterium avium complex J Antimicrob Chemother 35 1995 675 679
26. B.A. Brown, S.C. Ward, and C.J. Crist In vitro activity of linezolid against multiple species of Nocardia: a new drug of choice for a difficult disease? [abstract U-57] Program and Abstracts of the 100th General Meeting of the American Society for Microbiology 2000 American Society for Microbiology Washington, DC
27. Zyvox [package insert] 2000 Pharmacia & Upjohn Kalamazoo, MI
28. R.C. Moellering Jr Linezolid: the first oxazolidinone antimicrobial Ann Intern Med 138 2003 135 142
29. S.E. Duvall, J.B. Bruss, and M.A. McConnell-Martin Comparison of oral linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: results from a multinational phase III trial [abstract 80.005] Program and Abstracts of the 9th International Congress on Infectious Diseases 2000 International Society of Infectious Diseases Boston
30. J.F. Plouffe Emerging therapies for gram-positive bacterial infections Clin Infect Dis 31 Suppl 4 2000 S144 S149
31. J.B. Bruss, S.E. Duvall, and M.A. McConnell-Martin Comparison of linezolid to oxacillin followed by oral dicloxacillin in the treatment of complicated skin infections: results from a multinational phase III trial [abstract] Program and Abstracts of the 9th International Congress on Infectious Diseases 2000 International Society of Infectious Diseases Boston
32. D.L. Stevens, L.G. Smith, and J.B. Bruss Randomized comparison of linezolid (PNU-100766) versus oxacillin/dicloxacillin for the treatment of complicated skin and soft tissue infections Antimicrob Agents Chemother 44 2000 3408 3413
33. Cammarata S.K., San Pedro G.S., Timm J.A., et al. Comparison of Linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia [abstract]. Presented at the European Congress of Clinical Microbiology and Infectious Diseases. Stockholm, Sweden, May 28-31, 2000
34. M.E. Brier, D.J. Stalker, and G.R. Aronoff Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis [abstract A-54] Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy 1998 American Society for Microbiology Washington, DC
35. N. Rao, B.H. Ziran, and M.M. Wagener Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections Clin Infect Dis 38 2004 1058 1064
36. P.E. Hendershot, E.J. Antal, and I.R. Welshman Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl phenylpropanolamine HCl, and dextromethorphan HBr J Clin Pharmacol 41 2001 563 572
37. S.L. Green, J.C. Maddox, and E.D. Huttenbach Linezolid and reversible myelosuppression [letter] JAMA 285 2001 1291
38. Linezolid (Zyvox) Med Lett Drugs Ther 42 2000 45 46
39. D.R. Allington, and M.P. Rivey Quinupristin/dalfopristin: a therapeutic review Clin Ther 23 2001 24 44
40. M. David Livermore Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 46 2000 347 350
41. D.H. Batts, B.S. Lavin, and G.M. Eliopoulos Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy: a status report Curr Clin Top Infect Dis 21 2001 227 251
42. K.V. Singh, G.M. Weinstock, and B.E. Murray An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin Antimicrob Agents Chemother 46 2002 1845 1850
43. R.L. Nichols, D.R. Graham, S.L. Barriere for the Synercid Skin and Skin Structure Infection Group Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin J Antimicrob Chemother 44 1999 263 273
44. J. Beal for the Global Synercid SSSI Study Group Randomized, comparative, multicenter, open study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (cefazolin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI) [abstract 2318] Programme and Abstracts of the Twentieth International Congress of Chemotherapy 1997 International Society of Chemotherapy Sydney, Australia
45. J.-Y. Fagon, H. Patrick, D.W. Haas for the Nosocomial Pneumonia Group Treatment of gram-positive nosocomial pneumonia. prospective randomized comparison of quinupristin/dalfopristin versus vancomycin Am J Respir Crit Care Med 161 2000 753 762
46. H. Nadler, M.J. Dowzicky, and C. Feger Quinupristin/dalfopristin: a novel selective-spectrum antibiotic for the treatment of multi-resistant and other gram-positive pathogens Clinical Microbiology Newsletter 21 July 1, 1999 103 112
47. E. Rubinstein, P. Prokocimer, and G.H. Talbot Safety and tolerability of quinupristin/dalfopristin: administration guidelines J Antimicrob Chemother 44 1999 37 46
48. K.M. Olsen, J.A. Rebuck, and M.E. Rupp Arthralgias and myalgias related to quinupristin-dalfopristin administration Clin Infect Dis 32 2001 83 86
49. S.J. Rehm, D.R. Graham, and L. Srinath Successful administration of quinupristin/dalfopristin in the outpatient setting J Antimicrob Chemother 47 2001 639 645
50. D.L. Saravolatz, and J. Leggett Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones Clin Infect Dis 37 2003 1210 1215
51. G.A. Tarshis, B.M. Miskin, and T.M. Jones Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study Antimicrob Agents Chemother 45 2001 2358 2362
52. R. Muijsers, and B. Jarvis Moxifloxacin in uncomplicated skin and skin structure infections Drugs 62 2002 967 973
53. Gatifloxacin and moxifloxacin: two new fluoroquinolones Med Lett 42 2000 15 17
54. R.J. Roberge, R. Kaplan, and R. Frank Glyburide-ciprofloxacin interaction with resistant hypoglycemia Ann Emerg Med 36 2000 160 163
55. Tequin (gatifloxacin) [package insert] 2002 Bristol-Myers Squibb Princeton, NJ
56. D.M. Grasela Clinical pharmacology of gatifloxacin, a new fluoroquinolone Clin Infect Dis 31 Suppl 2 2000 S51 S58
57. M. Tristani-Firouzi, J. Chen, and J.S. Mitcheson Molecular biology of K+ channels and their role in cardiac arrhythmias Am J Med 110 2001 50 59
58. R. Gaynes, D. Rimland, and E. Killum Outbreak of Clostridium difficile infections in a long-term nursing facility: association with gatifloxacin use Clin Infect Dis 38 2004 640 645
59. W.M. Scheld Maintaining fluoroquinolone class efficacy: review of influencing factors Emerg Infect Dis 9 2003 1 9
60. G. Candiani, M. Abbondi, and M. Borgonovi In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic J Antimicrob Chemother 44 1999 179 192
61. M. Stogniew, F. Pu, and J. Dowell Attributes of dalbavancin: well distributed, weekly dosing, and completely eliminated Clin Microbiol Infect 9 Suppl 1 2003 S291
62. E. Seltzer, M.B. Dorr, and B.P. Goldstein Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections Clin Infect Dis 37 2003 1298 1303
63. N.E. Allen, and T.I. Nicas Mechanism of action of oritavancin and related glycopeptide antibiotics FEMS Microbiol Rev 26 2003 511 532
64. R.N. Jones, M.S. Barrett, and M.E. Erwin In vitro activity and spectrum of LY333328, a novel glycopeptide derivative Antimicrob Agents Chemother 41 1997 488 493
65. G.W. Kaatz, S.M. Seo, and J.R. Aeschlimann Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis Antimicrob Agents Chemother 42 1998 981 983
66. N. Woodford Novel agents for the treatment of resistant gram-positive infections Expert Opin Investig Drugs 12 2003 117 137
67. Wasilewski M., Disch D., McGill J., et al. Equivalence of shorter course therapy with oritavancin compared to vancomycin-cephalexin in complicated skin/skin structure infections. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois, December 16-19, 2001 [Abstract no. UL-18]